Simulations Plus

Simulations Plus EBITDA Margin

Delisted·Oct 7, 2026

The EBITDA Margin of Simulations Plus (SLP) as of Nov 11, 2026 is -89.33 %. In the previous year, EBITDA Margin was 8.76 % — a change of -1,120.08% (lower).

EBITDA Margin

-89.33 %

YoY

-1,120.08%

Last updated:

EBITDA Margin of Simulations Plus is 2025 -89.33 % . EBITDA Margin of Simulations Plus was 2024 8.76 % . It decreases by -1,120.08% lower compared to the previous year.

The Simulations Plus EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
34.71 USD
Jan 1, 2019
31.35 USD
Jan 1, 2020
27.90 USD
Jan 1, 2021
24.22 USD
Jan 1, 2022
27.66 USD
Jan 1, 2023
14.64 USD
Jan 1, 2024
8.76 USD
Jan 1, 2025
-89.33 USD
The Simulations Plus EBITDA Margin history
YEAREBITDA MarginYoY
-89.33 %-1,120.08%
8.76 %-40.20%
14.64 %-47.06%
27.66 %+14.22%
24.22 %-13.21%
27.90 %-10.98%
31.35 %-9.70%
34.71 %+1.38%
34.24 %-5.45%
36.21 %+13.23%
31.98 %-17.44%
38.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

EBITDA Margin of Simulations Plus is -89.33 % in 2025.

EBITDA Margin of Simulations Plus changed from 8.76 % to -89.33 %, representing a -1,120.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Simulations Plus with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Simulations Plus

All Key Metrics — Simulations Plus